Tessa Therapeutics Funding Round

7/6/2023

Venture Equity

$200,000,000

Undisclosed

Tessa is poised to emerge as a true leader in the cell therapy industry given the significant potential of our autologous and allogeneic cell therapy platforms combined with the scale and sophistication of our technical operation.

Private & Independent

Biopharmaceutical

8 Temasek Boulevard, #24-02 Suntec Tower 3
Singapore, 038988
Singapore

Tessa Therapeutics is a clinical-stage biotechnology company developing a portfolio of novel next-generation cell therapies for cancer. Tessa is leading the way in CD30 targeting using cell therapy. CD30 is a well validated lymphoma target with homogenous expression in Classical Hodgkin Lymphoma and multiple subsets of non-Hodgkin Lymphomas. Tessa's approach to target CD30-positive cancers using CAR-T (Chimeric Antigen Receptor) cells has demonstrated excellent safety and efficacy in early clinical trials. Having received the RMAT and PRIME designation, Tessa is now advancing the therapy to a pivotal trial.